Literature DB >> 2365581

Silent cerebral ischemia in patients with chronic atrial fibrillation--a case-control study.

M Guidotti1, G Tadeo, S Zanasi, G Pellegrini.   

Abstract

The cerebral CT-scan results of 72 patients with chronic atrial fibrillation (AF) were compared to those of an age- and sex-matched control group, affected by muscle-tensive headache. None of the patients in the study had any neurologic symptoms. All were normal on neurologic examination. Mean age was 68 years in both groups. Patients with atrial fibrillation had a higher prevalence of hypertension, diabetes and hyperlipidemia, although the differences were not significant. Thirty-two patients (44.4%) with AF showed hypodense lesions on cerebral CT-scan, suggestive of small infarcts, whereas this finding was present only in eight control subjects (11.1%) (p less than 0.05). These results confirm in part the observations reported in literature and suggest a more thorough examination of the problem regarding the prophylaxis of thrombo-embolic risk in patients affected by chronic AF.

Entities:  

Mesh:

Year:  1990        PMID: 2365581     DOI: 10.1007/bf02937438

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  11 in total

1.  Prophylaxis of recurrent embolism of intracardiac origin; protracted anticoagulant therapy on an ambulatory basis.

Authors:  S W COSGRIFF
Journal:  J Am Med Assoc       Date:  1950-07-08

2.  Anticoagulation therapy for cardiogenic emboli to brain.

Authors:  F M Yatsu; J P Mohr
Journal:  Neurology       Date:  1982-03       Impact factor: 9.910

3.  Reducing risks of cerebral embolism.

Authors:  C M Fisher
Journal:  Geriatrics       Date:  1979-02

4.  Atrial fibrillation and cerebral embolism.

Authors:  A J Moss
Journal:  Arch Neurol       Date:  1984-07

5.  Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study.

Authors:  F N Brand; R D Abbott; W B Kannel; P A Wolf
Journal:  JAMA       Date:  1985-12-27       Impact factor: 56.272

6.  Recurrent embolic cerebral infarction and anticoagulation.

Authors:  R L Koller
Journal:  Neurology       Date:  1982-03       Impact factor: 9.910

7.  Silent cerebral infarction in chronic atrial fibrillation.

Authors:  P Petersen; E B Madsen; B Brun; F Pedersen; C Gyldensted; G Boysen
Journal:  Stroke       Date:  1987 Nov-Dec       Impact factor: 7.914

8.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.

Authors:  P A Wolf; T R Dawber; H E Thomas; W B Kannel
Journal:  Neurology       Date:  1978-10       Impact factor: 9.910

9.  Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease.

Authors:  J I Sage; R L Van Uitert
Journal:  Stroke       Date:  1983 Jul-Aug       Impact factor: 7.914

Review 10.  Management of cerebral embolism of cardiac origin.

Authors:  J D Easton; D G Sherman
Journal:  Stroke       Date:  1980 Sep-Oct       Impact factor: 7.914

View more
  4 in total

Review 1.  Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis.

Authors:  Shadi Kalantarian; Hakan Ay; Randy L Gollub; Hang Lee; Kallirroi Retzepi; Moussa Mansour; Jeremy N Ruskin
Journal:  Ann Intern Med       Date:  2014-11-04       Impact factor: 25.391

Review 2.  Atrial fibrillation in the elderly: facts and management.

Authors:  Guy Chatap; Karine Giraud; Jean-Pierre Vincent
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Implications of silent strokes.

Authors:  Frank M Yatsu; Hashem M Shaltoni
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

4.  Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals.

Authors:  Yu Han Koh; Leslie Z W Lew; Kyle B Franke; Adrian D Elliott; Dennis H Lau; Anand Thiyagarajah; Dominik Linz; Margaret Arstall; Phillip J Tully; Bernhard T Baune; Dian A Munawar; Rajiv Mahajan
Journal:  Europace       Date:  2022-09-01       Impact factor: 5.486

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.